

**Bedeutung und Perspektiven der Modifikation des Tumormicroenvironments  
in der Behandlung von kolorektalen Karzinomen (S. 14–18)**

*B. A. Koch, L. Uflacker*

**Literatur:**

1. Witz IP. The tumor microenvironment: the making of a paradigm. *Cancer Microenviron* 2009; 2 Suppl 1(Suppl 1): 9–17
2. Koch B et al. The analysis of mononuclear cell infiltrations in colorectal adenocarcinoma. *J Cancer Res Clin Oncol* 1985; 109: 142–51
3. Liekens S et al. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. *Biochem Pharmacol* 2007; 74(11): 1555–67
4. Komatsu T et al. Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver. *Clin Cancer Res* 2001; 7(3): 675–81
5. Reigner B et al. Clinical pharmacokinetics of capecitabine. *Clin Pharmacokinet* 2001; 40(2): 85–104
6. Fox SB et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. *J Pathol* 1995; 176: 183–90
7. Ciccolini J et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. *Mol Cancer Ther* 2002; 1(11): 923–27
8. Lenz HJ et al. TAS-102, a novel antitumor agent: a review of the mechanism of action. *Cancer Treat Rev* 2015; 41(9): 777–83
9. Gottfried E et al. Expression of CD68 in non-myeloid cell types. *Scand J Immunol* 2008; 67(5): 453–63
10. Hoff PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001; 19(8): 2282–92
11. Derksen JWG et al. Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. *Eur J Cancer* 2022; 166: 73–86
12. Bruni D et al. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. *Nat Rev Cancer* 2020; 20(11): 662–80
13. Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* 2002; 29(6 Suppl 16): 15–18
14. Zhang Y et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. *Proc Natl Acad Sci USA* 2017; 114(26): E5226–E5235
15. Des Guetz G et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. *Br J Cancer* 2006; 94(12): 1823–32

16. Mohamed SY et al. Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases. *J Gastrointest Cancer* 2019; 50(1): 23–34
17. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; 350(23): 2335–42
18. Cunningham D et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. *Lancet Oncol* 2013; 14(11): 1077–85
19. Simkens LHJ et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancet* 2015; 385(9980): 1843–52
20. Van Cutsem E et al. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. *Target Oncol* 2016; 11(3): 383–400
21. Tabernero J et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. *Lancet Oncol* 2015; 16(5): 499–508
22. Li J et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. *JAMA* 2018; 319(24): 2486–96
23. Grothey A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381(9863): 303–12
24. Mayer RJ et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. *N Engl J Med* 2015; 372(20): 1909–19
25. Liu CJ et al. TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer. *Gastroenterol Res Pract* 2021; 2021: 4014601
26. Pfeiffer P et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. *Lancet Oncol* 2020; 21(3): 412–20
27. Cercek A et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. *N Engl J Med* 2022; 386(25): 2363–76
28. Diaz LA et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. *Lancet Oncol* 2022; 23(5): 659–70
29. Gordon SR et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* 2017; 545(7655): 495–99
30. Korehisa S et al. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. *Int J Cancer* 2018; 142(4): 822–32
31. Limagne E et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. *Cancer Immunol Res* 2019; 7(12): 1958–69

32. Doleschel D et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth. *J Exp Clin Cancer Res* 2021; 40(1): 288
  33. Lan J et al. M2 Macrophage-Derived Exosomes Promote Cell Migration and Invasion in Colon Cancer. *Cancer Res* 2019; 79(1): 146–58
  34. Paladhi A et al. Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity, *Front Immunol* 2022; 13: 988701
  35. Montalban-Hernandez K et al. Colorectal Cancer Stem Cells Fuse with Monocytes to Form Tumour Hybrid Cells with the Ability to Migrate and Evade the Immune System. *Cancers* 2022; 14(14): 3445
- 

## Ein Ausschnitt aus den Indikationen von CAR-T-Zell-Therapien in der pädiatrischen Onkologie (S. 21–25)

A. Attarbaschi

### Literatur:

1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. *N Engl J Med* 2015; 373(16): 1541–52
2. Testi AM et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. *Eur J Cancer* 2019; 122: 61–71
3. Pui CH. Precision medicine in acute lymphoblastic leukemia. *Front Med* 2020; 14(6): 689–700
4. Brivio E et al. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series. *Br J Haematol* 2021; 193(6): 1172–7
5. Minard-Colin V et al. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. *N Engl J Med* 2020; 382(23): 2207–19
6. von Stackelberg A et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *J Clin Oncol* 2016; 34(36): 4381–9
7. Brivio E et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). *Blood* 2021; 137(12): 1582–90
8. Gore L et al. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. *Blood Cancer J* 2018; 8(9): 80
9. Jacoby E et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. *Leukemia* 2022; 36(6): 1525–32
10. Maude SL. Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia. *Clin Adv Hematol Oncol* 2018; 16(10): 664–6
11. Maude SL et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med* 2018; 378(5): 439–48

12. Levine JE et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. *J Immunother Cancer* 2021; 9(8)
  13. Ghorashian S et al. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. *Lancet Haematol* 2022; 9(10): e766-e75
  14. Myers RM, Shah NN, Pulsipher MA. How We Use Risk Factors for Success or Failure of CD19 CAR T-cells to Guide Management of Children/AYA with B-cell ALL. *Blood* 2022. blood.2022016937
  15. Dourthe ME et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. *Leukemia* 2021; 35(12): 3383–93
  16. Attarbaschi A et al. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. *Leukemia* 2020; 34(6): 1694–700
  17. Attarbaschi A et al. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. *J Clin Oncol* 2022: JCO2201297
  18. Conter V et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. *Blood* 2010; 115(16): 3206–14
  19. Schrappe M et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. *Blood* 2011; 118(8): 2077–84
  20. Teachey DT. New approaches to T-cell acute lymphoblastic leukemia. *Clin Adv Hematol Oncol* 2022; 20(5): 295–8
  21. Summers RJ, Teachey DT. SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma. *Clin Lymphoma Myeloma Leuk* 2022; 22(10): 718–25
  22. Png YT et al. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. *Blood Adv* 2017; 1(25): 2348–60
- 

## **Update: Neues zur Diagnostik, Prognoseabschätzung und Therapie der Myelodysplastischen Syndrome (S. 27–33)**

*A. Kasprzak, C. Strupp, K. Nachtkamp, D. Haase, N. Gattermann, U. Germing*

### **Literatur:**

1. Khoury JD et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022; 36(7): 1703–719
2. Bernard E et al. 2021. Molecular International Prognosis Scoring System for Myelodysplastic Syndromes. *NEJM Evid* 2022; 1(7)
3. Neukirchen J et al. Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. *Leuk Res* 2011; 35(12): 1591–6

4. Kuendgen A et al. Myelodysplastic syndromes in patients younger than age 50. *J Clin Oncol* 2006; 24(34): 5358–65
5. Kuendgen A et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. *Leukemia* 2021;35(3): 835–849
6. Feuerstein S et al. Germline variants drive myelodysplastic syndrome in young adults. *Leukemia* 2021; 35(8): 2439–44
7. Bernard E et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat Med* 2020; 26(10): 1549–56
8. Arber DA et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood* 2022; 140(11): 1200–28
9. Neukirchen J et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. *Leuk Res* 2014; 38(1): 57–64
10. Zipperer E et al. The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. *Haematologica* 2014; 99(3): e31-2
11. Malcovati L et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. *Blood* 2013; 122(17):2943–64
12. Hofmann W-K et al. *Onkopedia: Myelodysplastische Syndrome*, März 2022
13. Gattermann N et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. *Haematologica* 2012; 97(9):1364-71
14. Hoeks M et al. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. *Leukemia* 2021; 35(6): 1745–50
15. Santini V et al. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. *Leuk Lymphoma* 2020; 61(6): 1475–83
16. Schuler E et al. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). *Leukemia* 2016; 30(7): 1580–2
17. Fenaux P et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. *New England Journal of Medicine* 2020; 382(2): 140–51
18. de Witte T et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. *Blood* 2017; 129(13): 1753–62
19. Kobbe G et al. The current and future role of stem cells in myelodysplastic syndrome therapies. *Expert Rev Hematol* 2018; 11(5): 411–22
20. Kröger N et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). *J Clin Oncol* 2021; 39(30): 3318–27
21. Schroeder T et al. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia. *Biol Blood Marrow Transplant* 2019; 25(8): 1550–9
22. Schroeder T et al. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions - a

- retrospective multicenter analysis from the German Cooperative Transplant Study Group. *Biol Blood Marrow Transplant* 2015; 21(4): 653–60
23. Schroeder T et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. *Ann Hematol* 2018; 97(2): 335–42
  24. Rautenberg C et al. Wilm's Tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. *Bone Marrow Transplant* 2021; 56(2):442–50
  25. Zeidan AM et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. *Am J Hematol* 2022. 2023; 98(2): 272–81
- 

## Neues zum Anaplastischen Schilddrüsenkarzinom – ein Update (S. 34–38)

*T. Brandenburg, Y. M. Machlah, D. Führer*

### **Literatur:**

1. Tuttle R M, Haugen B. & Perrier N D. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? *Thyroid* 2017; 27: 751
2. Baloch Z W et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr. Pathol* 2022; 33(1): 27–63
3. Tiedje V et al. Anaplastic thyroid carcinoma: Review of treatment protocols. *Endocrine-Related Cancer* 2018; 25: R153–R1614. Filetti S et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. *Ann Oncol Off J Eur Soc Med Oncol* 2022; 33: 674–84
5. Bible K C et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. *Thyroid* 2021; 31: 337–3866. Ito Y et al. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. *Thyroid* 2017; 27: 1142–1148
7. Ravaud A et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. *Eur J Cancer* 2017; 76: 110–17
8. Bible K C et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. *J Clin Endocrinol Metab* 2012; 97: 3179–84
9. Cabanillas M E, Ryder M & Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. *Endocr Rev* 2019; 40: 1573–604
10. Ravaud A et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. *Eur J Cancer* 2017; 76: 110–17
11. Wirth L J et al. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. *J Clin Oncol* 2021; 39: 2359–66

12. Sparano C et al. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. *Endocr Relat Cancer* 2021; 28: 15–26
13. Kim S Y et al. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis. *Front Endocrinol (Lausanne)* 2020; 11
14. Kim M et al. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. *Endocrine* 2021; 71: 427–33
15. Takahashi S et al. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. *Adv Ther* 2020; 37: 3850–62
16. Subbiah V et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600–mutant anaplastic thyroid cancer. *J Clin Oncol* 2018; 36: 7–13
17. Subbiah V et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. *Ann Oncol* 2022; 33: 406–15
18. Wang J R et al. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. *Thyroid* 2019; 29: 1036–43
19. Maniakas A et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000–2019. *JAMA Oncol* 2020; 6: 1397–404
20. Wirth L J et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. *N Engl J Med* 2020; 383: 825–35
21. Xu B et al. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. *Thyroid* 2020; 30(10): 1505–17
22. Drilon A et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med* 2018; 378: 731–39
23. Hong D S et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 2020; 21: 531
24. Waguespack S G et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. *Eur J Endocrinol* 2022; 186: 631–43
25. Doebele R C et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. *Lancet Oncol* 2020; 21: 271–82
26. Demetri G D et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. *Clin Cancer Res* 2022; 28: 1302–312
27. Godbert Y et al. Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. *J Clin Oncol* 2015; 33: e84–e87
28. Leroy L et al. Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib. *Thyroid* 2020; 30: 343–44
29. Lim S M et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. *Ann Oncol Off J Eur Soc Med Oncol* 2013; 24: 3089–93
30. Wagle N et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. *N Engl J Med* 2014; 371: 1426–33

31. Dias-Santagata D et al. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. *Thyroid* 2020; 30: 1384–89
32. Bible K C et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force. *Thyroid* 2021; 31(3): 337–86
33. Landa I et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. *J Clin Invest* 2016; 126: 1052–66
34. Tiedje V et al. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. *Oncotarget* 2017; 8: 42613–620
35. Capdevila J et al. PD-1 blockade in anaplastic thyroid carcinoma. *J Clin Oncol* 2020; 38: 2620–27
36. Shih S R et al. Immunotherapy in anaplastic thyroid cancer: Case series. *J Formos Med Assoc* 2022; 121: 1167–73
37. Lorch J H et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radiiodine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). *J Clin Oncol* 2020; 38: 6513–13
38. Dierks C et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. *Thyroid* 2021; 31: 1076–85
39. Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma | OncologyPRO. Available at: <https://oncologypro.esmo.org/meeting-resources/esmo-congress/phase-ii-atlep-trial-final-results-for-lenvatinib-pembrolizumab-in-metastasized-anaplastic-and-poorly-differentiated-thyroid-carcinoma>. Letzter Zugriff: 5. Januar 2023
40. Hatashima A et al. An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma. *Thyroid* 2022; 32(8): 926–36
41. Iyer P C et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. *J Immunother Cancer* 2018; 6: 1–10
42. Bojarsky M et al. Outcomes of a low-risk pediatric thyroid cancer patients not treated with radioactive iodine therapy. American Thyroid Association 2022 Annual Meeting, Late breaking oral 46. Published online 11 Oct 2022: <https://www.liebertpub.com/doi/10.1089/thy.2022.29140.lb.abstracts>
43. Cabanillas M E et al. Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC). *J Clin Oncol* 2020; 38: 6514–14
44. Kollipara R, Schneider B, Radovich M et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer. *Oncologist* 2017; 22(10): 1149–51
45. Cabanillas M E et al. Neoadjuvant BRAF-and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. *Thyroid* 2018; 28: 945–51